Canadian Centre for Agri-Food Research in Health and Medicine, Winnipeg, MB R2H 2A6, Canada.
Agriculture and Agri-Food Canada, Winnipeg, MB R3C 1B2, Canada.
Molecules. 2021 Oct 31;26(21):6600. doi: 10.3390/molecules26216600.
Atherosclerosis, myocardial infarction (MI) and heart failure (HF) are the main causes of mortality and morbidity around the globe. New therapies are needed to better manage ischemic heart disease and HF as existing strategies are not curative. Resveratrol is a stilbene polyphenolic compound with favorable biological effects that counter chronic diseases. Current evidence suggests that resveratrol is cardioprotective in animal models of atherosclerosis, ischemic heart disease, and HF. Though clinical studies for resveratrol have been promising, evidence remains inadequate to introduce it to the clinical setting. In this narrative review, we have comprehensively discussed the relevant compelling evidence regarding the efficacy of resveratrol as a new therapeutic agent for the management of atherosclerosis, MI and HF.
动脉粥样硬化、心肌梗死（MI）和心力衰竭（HF）是全球范围内死亡和发病的主要原因。需要新的治疗方法来更好地管理缺血性心脏病和 HF，因为现有的治疗策略无法治愈这些疾病。白藜芦醇是一种具有良好生物学效应的二苯乙烯多酚化合物，可对抗慢性疾病。现有证据表明，白藜芦醇在动脉粥样硬化、缺血性心脏病和 HF 的动物模型中具有心脏保护作用。虽然白藜芦醇的临床研究很有前景，但仍缺乏足够的证据将其引入临床实践。在本综述中，我们全面讨论了关于白藜芦醇作为治疗动脉粥样硬化、MI 和 HF 的新治疗剂的疗效的相关有力证据。
